Cargando…

Prescription Patterns of New Use of Fixed-Dose Combination Inhalers in Patients with Chronic Obstructive Pulmonary Disease: Long-Acting β2 Agonists Plus Long-Acting Muscarinic Antagonists versus Long-Acting β2 Agonists Plus Inhaled Corticosteroids

BACKGROUND: The clinical guideline recommends use of long-acting β2 agonists/long-acting muscarinic antagonists (LABA/LAMA) or long-acting β2 agonists/inhaled corticosteroids (LABA/ICS) combination therapies for patients with severe chronic obstructive pulmonary disease (COPD). The fixed-dose combin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liao, Pei-An, Pan, Sheng-Wei, Chen, Chun-Yu, Deng, Chung-Yeh, Dong, Yaa-Hui
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2023
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10105570/ https://www.ncbi.nlm.nih.gov/pubmed/37069844 http://dx.doi.org/10.2147/COPD.S393392

Ejemplares similares

Comparison of pneumonia incidence between long-acting muscarinic antagonist and inhaled corticosteroid plus long-acting beta agonist in patients with COPD
por: Lee, Eung Gu, et al.
Publicado: (2023)

Blood eosinophils and inhaled corticosteroid/long-acting β-2 agonist efficacy in COPD
por: Pavord, Ian D, et al.
Publicado: (2016)

Effect of Adding Inhaled Corticosteroid to Long-Acting Muscarinic Antagonist/Long-Acting Beta-Agonist Therapy Among Patients With Chronic Obstructive Pulmonary Disease
por: Yuasa, Mizuki, et al.
Publicado: (2021)

Optimal Bronchodilation for COPD Patients: Are All Long-Acting β(2)-Agonist/Long-Acting Muscarinic Antagonists the Same?
por: Miravitlles, Marc, et al.
Publicado: (2018)

An assessment of asthma exacerbations in pediatric patients using a long-acting B2-agonist plus inhaled corticosteroid versus an inhaled corticosteroid alone
por: Alakeel, Yousif S., et al.
Publicado: (2022)

Low adherence to inhaled corticosteroids/long-acting β(2)-agonists and biologic treatment in severe asthmatics
por: Caminati, Marco, et al.
Publicado: (2020)

Estimating Inhaled Corticosteroid Exposure from Short-Acting β(2)-Agonist–Inhaled Corticosteroid Rescue
por: Lugogo, Njira, et al.
Publicado: (2023)

Long-acting muscarinic antagonists vs. long-acting β (2) agonists in COPD exacerbations: a systematic review and meta-analysis
por: Maia, Israel Silva, et al.
Publicado: (2017)

A Network Meta-Analysis of Long-Acting Muscarinic Antagonist (LAMA) and Long-Acting β(2)-Agonist (LABA) Combinations in COPD
por: Sion, Katya Y. J., et al.
Publicado: (2017)

Transcriptome analysis in patients with asthma after inhaled combination therapy with long-acting β2-agonists and corticosteroids
por: Liang, Ya-Ru, et al.
Publicado: (2022)

Prescribing of long-acting beta-2-agonists/inhaled corticosteroids after the SMART trial
por: Rottenkolber, Marietta, et al.
Publicado: (2015)

Impact of adherence to treatment with inhaled corticosteroids/long-acting β-agonists on asthma outcomes in the United States
por: Averell, Carlyne M., et al.
Publicado: (2022)

A randomized controlled trial of long-acting muscarinic antagonist and long-acting β2 agonist fixed-dose combinations in patients with chronic obstructive pulmonary disease
por: Muraki, Masato, et al.
Publicado: (2021)

Effects of a single long-acting muscarinic antagonist agent and a long-acting muscarinic antagonist/long-acting β2-adrenoceptor agonist combination on lung function and symptoms in untreated COPD patients in Japan
por: Yamada, Hideyasu, et al.
Publicado: (2018)

Systematic review and network meta-analysis of the efficacy and safety of glycopyrrolate/formoterol fumarate metered dose inhaler in comparison with other long-acting muscarinic antagonist/long-acting β(2)-agonist fixed-dose combinations in COPD
por: Siddiqui, Mohd Kashif, et al.
Publicado: (2019)

Characterization of Patients with Chronic Obstructive Pulmonary Disease Initiating Single-Inhaler Long-Acting Muscarinic Antagonist/Long-Acting β(2)-Agonist Dual Therapy in a Primary Care Setting in England
por: Requena, Gema, et al.
Publicado: (2022)

A smarter way to manage asthma with a combination of a long-acting β(2)-agonist and inhaled corticosteroid
por: Selroos, Olof
Publicado: (2007)

Long-acting beta-agonists plus inhaled corticosteroids safety: a systematic review and meta-analysis of non-randomized studies
por: Hernández, Gimena, et al.
Publicado: (2014)

Severe exacerbation and pneumonia in COPD patients treated with fixed combinations of inhaled corticosteroid and long-acting beta2 agonist
por: Yang, Hsi-Hsing, et al.
Publicado: (2017)

Risk of sepsis among patients with COPD treated with fixed combinations of inhaled corticosteroids and long-acting Beta2 agonists
por: Wang, Cheng-Yi, et al.
Publicado: (2019)

The role of long-acting muscarinic antagonist/long-acting β agonist fixed-dose combination treatment for chronic obstructive pulmonary disease in China: a narrative review
por: Zhou, Ji’an, et al.
Publicado: (2021)

Add-on Therapy for Symptomatic Asthma despite Long-Acting Beta-Agonists/Inhaled Corticosteroid
por: Dreher, Michael, et al.
Publicado: (2018)

Efficacy and safety of the CRTh2 antagonist AZD1981 as add-on therapy to inhaled corticosteroids and long-acting β(2)-agonists in patients with atopic asthma
por: Bateman, Eric D, et al.
Publicado: (2018)

Successful treatment with inhaled corticosteroid/long-acting β(2)-agonist in a case of allergic bronchopulmonary mycosis caused by Schizophyllumcommune
por: Sekiya, Muneyuki, et al.
Publicado: (2023)

Risk of active tuberculosis among COPD patients treated with fixed combinations of long-acting beta2 agonists and inhaled corticosteroids
por: Huang, Tsan-Ming, et al.
Publicado: (2020)

Efficacy of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Versus Other Inhaled Corticosteroid/Long-Acting Muscarinic Antagonist/Long-Acting β(2)-Agonist (ICS/LAMA/LABA) Triple Combinations in COPD: A Systematic Literature Review and Network Meta-analysis
por: Ferguson, Gary T., et al.
Publicado: (2020)

The impact of poor asthma control among asthma patients treated with inhaled corticosteroids plus long-acting β(2)-agonists in the United Kingdom: a cross-sectional analysis
por: Pavord, Ian D., et al.
Publicado: (2017)

Treatment Patterns, Healthcare Utilization and Clinical Outcomes of Patients with Chronic Obstructive Pulmonary Disease Initiating Single-Inhaler Long-Acting β(2)-Agonist/Long-Acting Muscarinic Antagonist Dual Therapy in Primary Care in England
por: Requena, Gema, et al.
Publicado: (2023)

Impact of changes to reimbursement of fixed combinations of inhaled corticosteroids and long-acting β(2)-agonists in obstructive lung diseases: a population-based, observational study
por: Björnsdóttir, U S, et al.
Publicado: (2014)

Risk of pneumonia with inhaled corticosteroid/long-acting β2 agonist therapy in chronic obstructive pulmonary disease: a cluster analysis
por: DiSantostefano, Rachael L, et al.
Publicado: (2014)

Physicians’ attitudes towards combination therapy with inhaled corticosteroids and long-acting β(2)-agonists: an observational study in UK specialist care
por: Thomas, Mike, et al.
Publicado: (2011)

Combined inhaled corticosteroid and long-acting β2-adrenergic agonist therapy for noncystic fibrosis bronchiectasis with airflow limitation: An observational study
por: Wei, Ping, et al.
Publicado: (2016)

Effects of roflumilast in COPD patients receiving inhaled corticosteroid/long-acting β(2)-agonist fixed-dose combination: RE(2)SPOND rationale and study design
por: Rennard, Stephen I, et al.
Publicado: (2016)

Clinical pharmacokinetics of AZD3199, an inhaled ultra-long-acting β(2)-adrenoreceptor agonist (uLABA)
por: Bjermer, Leif, et al.
Publicado: (2015)

Pneumonia and pneumonia related mortality in patients with COPD treated with fixed combinations of inhaled corticosteroid and long acting β(2) agonist: observational matched cohort study (PATHOS)
por: Janson, Christer, et al.
Publicado: (2013)

Pneumonia and pneumonia related mortality in patients with COPD treated with fixed combinations of inhaled corticosteroid and long acting β2 agonist: observational matched cohort study (PATHOS)
Publicado: (2013)

Which inhaled corticosteroid and long-acting β-agonist combination is better in patients with moderate-to-severe asthma, a dry powder inhaler or a pressurized metered-dose inhaler?
por: Muraki, Masato, et al.
Publicado: (2017)

Therapeutic preferences and factors determining the use of inhaled corticosteroids with long-acting β(2)-agonists in patients with asthma and chronic obstructive pulmonary disease
por: Olszanecka-Glinianowicz, Magdalena, et al.
Publicado: (2020)

Effects of Roflumilast on Patients with Chronic Obstructive Pulmonary Disease Treated with Inhaled Corticosteroid/Long-Acting β2 Agonist: A Meta-analysis
por: Zeng, Shasha, et al.
Publicado: (2022)

Efficacy and safety of single-inhaler extrafine triple therapy versus inhaled corticosteroid plus long-acting beta2 agonist in eastern Asian patients with COPD: the TRIVERSYTI randomised controlled trial
por: Zheng, Jinping, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_q2stkgecpv9ga87fte6rgigcbg